Compass Therapeutics reports positive Phase 2 data for CTX-009 in biliary tract cancers; ORR 37.5%

Compass Therapeutics, Inc.

CTX-009 + paclitaxel achieved 37.5% ORR in 24 patients; second-line sub-group ORR 63.6% (7/11 PRs).
Median PFS 9.4 months, median OS 12.5 months; data to be presented at ASCO GI on Jan 20, 2023.
Randomized Phase 2/3 trial (up to 150 patients) initiated in US; may enable BLA submission in H2 2024.
Safety consistent with prior studies; Grade 3+ TEAEs included decreased neutrophils (83.3%), hypertension (16.7%).
Investor webcast scheduled for Jan 23 at 8:30am ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.